Citations (107)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (29)
Ning Ma, Lei Zhang, Wufang Zhang, Yingying He, Chong Ye & Xin Li. (2023) Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review. Neuropsychiatric Disease and Treatment 19, pages 1987-2006.
Read now
Read now
Dusica Hadzi Boskovic, Shuting Liang, Purva Parab, Emily Wiggins & Joshua N Liberman. (2023) Real-World Evidence of Aripiprazole Tablets with Sensor: Treatment Patterns and Impacts on Psychiatric Healthcare Resource Utilization. ClinicoEconomics and Outcomes Research 15, pages 487-498.
Read now
Read now
Stine Lassen, Thale Heintz, Tilde Pedersen, Christian Jentz, Naaja Nathanielsen, Parnuna Heilmann & Lisbeth Uhrskov Sørensen. (2023) Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients. International Journal of Circumpolar Health 82:1.
Read now
Read now
Heidi C. Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee & Leslie Citrome. (2023) The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of Medical Economics 26:1, pages 316-325.
Read now
Read now
Simon Fifer, Brittany Keen, Richard Newton, Andrea Puig & Marija McGeachie. (2022) Understanding the Treatment Preferences of People Living with Schizophrenia in Australia; A Patient Value Mapping Study. Patient Preference and Adherence 16, pages 1687-1701.
Read now
Read now
Maria Paz Garcia-Portilla, Adolfo Benito Ruiz, Felisa Gómez Robina, Marta García Dorado & Paola María López Rengel. (2022) Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study. Expert Opinion on Pharmacotherapy 23:5, pages 629-638.
Read now
Read now
Monica Zolezzi, Rawan Abouelhassan, Yassin Eltorki, Peter M Haddad & Mahtab Noorizadeh. (2021) Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile. Neuropsychiatric Disease and Treatment 17, pages 1917-1926.
Read now
Read now
Francesco Pietrini, Lorenzo Tatini, Gabriele Santarelli, Dario Brugnolo, Marco Squillace, Bernardo Bozza, Andrea Ballerini, Valdo Ricca & Giulio D’Anna. (2021) Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study. International Journal of Psychiatry in Clinical Practice 25:3, pages 307-315.
Read now
Read now
Michael J Doane, Martha Sajatovic, Peter J Weiden, Amy K O’Sullivan, Stephen Maher, Jakob B Bjorner, Asia Sikora Kessler, Julia Carpenter-Conlin, Leona Bessonova & Dawn I Velligan. (2020) Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey. Patient Preference and Adherence 14, pages 2043-2054.
Read now
Read now
Clifton Blackwood, Panna Sanga, Isaac Nuamah, Alexander Keenan, Arun Singh, Maju Mathews & Srihari Gopal. (2020) Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire. Patient Preference and Adherence 14, pages 1093-1102.
Read now
Read now
Wagner F Gattaz, Ricardo Saracco-Alvarez, Claudiane Salles Daltio, Martinus T Van de Bilt, Jose Julian Ortegón, Sergio J Villaseñor-Bayardo, Mario Louzã, Helio Elkis, Bernardo Soares, Patricia Cabrera Jaramillo, Fabio Lawson & Leonardo Díaz-Galvis. (2020) Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability. Neuropsychiatric Disease and Treatment 16, pages 2063-2072.
Read now
Read now
Francesco Pietrini, Umberto Albert, Andrea Ballerini, Paola Calò, Giuseppe Maina, Federica Pinna, Marco Vaggi, Ileana Boggian, Maria Fontana, Cesare Moro & Bernardo Carpiniello. (2019) The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1045-1060.
Read now
Read now
Nan Li, Jian Min Zhuo, Ibrahim Turkoz, Maju Mathews, Yu Feng & Wilson Tan. (2019) A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics. Expert Opinion on Pharmacotherapy 20:16, pages 2033-2039.
Read now
Read now
Xue Song, Antoine C. El Khoury, Matthew Brouillette, David Smith & Kruti Joshi. (2019) Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. Journal of Medical Economics 22:11, pages 1105-1112.
Read now
Read now
Bruno Emond, Antoine C. El Khoury, Charmi Patel, Dominic Pilon, Laura Morrison, Maryia Zhdanava, Patrick Lefebvre, Neeta Tandon & Kruti Joshi. (2019) Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. Current Medical Research and Opinion 35:3, pages 407-416.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Martha Sajatovic, Ruth Ross, Susan N Legacy, Christoph U Correll, John M Kane, Faith DiBiasi, Heather Fitzgerald & Matthew Byerly. (2018) Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1. Neuropsychiatric Disease and Treatment 14, pages 1463-1474.
Read now
Read now
Wenjie Zhang, Tony B Amos, Stephen W Gutkin, Nicole Lodowski, Emma Giegerich & Kruti Joshi. (2018) A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. ClinicoEconomics and Outcomes Research 10, pages 309-320.
Read now
Read now
Eduard Parellada, Miquel Bioque, Manuel Serrano, Berta Herrera & Marta García Dorado. (2018) An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study). International Journal of Psychiatry in Clinical Practice 22:3, pages 191-199.
Read now
Read now
Rosaria Di Lorenzo, Michela Cameli, Chiara Piemonte, Marisa Bolondi, Giulia Landi, Gabriella Pollutri, Ludovica Spattini, Valentina Moretti & Paola Ferri. (2018) Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting. Nordic Journal of Psychiatry 72:3, pages 214-220.
Read now
Read now
Solomon Nuhoho, Abdallah Saad, Goretti Saumell, Daniel Ribes & Antoine C. El Khoury. (2018) Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates. Current Medical Research and Opinion 34:4, pages 601-611.
Read now
Read now
Dominic Pilon, Matthew Alcusky, Yongling Xiao, Philippe Thompson-Leduc, Marie-Hélène Lafeuille, Patrick Lefebvre & Carmela Benson. (2018) Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. Journal of Medical Economics 21:2, pages 135-143.
Read now
Read now
Jingping Zhao, Lehua Li, Jianguo Shi, Yi Li, Xiufeng Xu, Keqing Li, Lili Zhang, Shangli Cai, Yu Feng, Jianmin Zhuo, Weihong Liu & Huafei Lu. (2017) Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. Neuropsychiatric Disease and Treatment 13, pages 2045-2056.
Read now
Read now
Eva G Katz, Brett Hauber, Srihari Gopal, Angie Fairchild, Amy Pugh, Rachel B Weinstein & Bennett S Levitan. (2016) Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Preference and Adherence 10, pages 2127-2139.
Read now
Read now
Andrea de Bartolomeis, Andrea Fagiolini, Marco Vaggi & Claudio Vampini. (2016) Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. Neuropsychiatric Disease and Treatment 12, pages 99-108.
Read now
Read now
Thomas R. Einarson, Hanna Pudas, Pushpendra Goswami, Kristel van Impe & Basil G. Bereza. (2016) Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. Journal of Medical Economics 19:2, pages 121-130.
Read now
Read now
Franck Jean Baylé, Arnaud Tessier, Sophie Bouju & David Misdrahi. (2015) Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone. Patient Preference and Adherence 9, pages 1333-1341.
Read now
Read now
Carmela J. Benson, Kruti Joshi, Kate L. Lapane & John Fastenau. (2015) Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics. Current Medical Research and Opinion 31:7, pages 1437-1448.
Read now
Read now
Francesco Pietrini, Mattia Spadafora, Gabriela Alina Talamba, Lucia Godini, Lorenzo Lelli, Susanna Arcabasso, Mara Manetti & Andrea Ballerini. (2015) The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results. International Journal of Psychiatry in Clinical Practice 19:2, pages 106-113.
Read now
Read now
Articles from other publishers (78)
Sophie Bou, Feifei Ng, Elise Guegain, Charlotte Peloso, Adolfo Lopez-Noriega & Mayeul Collot. (2023) Evaluating the in vivo stability of water-soluble PEG-PLA copolymers using FRET imaging. Reactive and Functional Polymers 187, pages 105579.
Crossref
Crossref
Eric D. Achtyes, Seth C. Hopkins, Nina Dedic, Heather Dworak, Courtney Zeni & Kenneth Koblan. (2023) Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience.
Crossref
Crossref
Inmaculada Baeza, Adriana Fortea, Daniel Ilzarbe & Gisela Sugranyes. (2023) What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review. Pediatric Drugs 25:2, pages 135-149.
Crossref
Crossref
Jihoon Oh, Jihye Oh, Dong Wook Kim, HyunChul Youn, Sae-Hoon Kim, Soo In Kim, In Won Chung, Kuan Shu Wang, Minah Kim, Jong-Woo Paik, Min Jung Koh, Yoosun Lee, Seok Young Choi & Jung-Jin Kim. (2023) Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience 21:1, pages 126-134.
Crossref
Crossref
Andrea L. Murphy, Sowon Suh, Louise Gillis, Jason Morrison & David M. Gardner. (2023) Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review. Pharmacy 11:2, pages 45.
Crossref
Crossref
Antonio Vita, Andrea Fagiolini, Giuseppe Maina, Claudio Mencacci, Edoardo Spina & Silvana Galderisi. (2023) Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic. Annals of General Psychiatry 22:1.
Crossref
Crossref
Ronaldo Portela, Milton Leonard Wainberg, Saulo Castel, Helian Nunes de Oliveira & Cristina Mariano Ruas. (2022) Risk factors associated with readmissions of patients with severe mental disorders under treatment with antipsychotics. BMC Psychiatry 22:1.
Crossref
Crossref
Giulio D'Anna, Francesco Rotella, Gabriele Santarelli, Silvia Scannerini, Alessandra Fanelli, Valdo Ricca & Andrea Ballerini. (2022) Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotics as a Predictor of Relapse in Schizophrenia Spectrum Disorders: A 1-Year Pilot Study. Therapeutic Drug Monitoring 44:6, pages 805-810.
Crossref
Crossref
Andrea Fagiolini, Eugenio Aguglia, Andrea Ballerini, Gaetano Callista, Bernardo Carpiniello, Massimo Clerici, Giulio Corrivetti, Alessandro Cuomo, Pasquale De Fazio, Sergio De Filippis, Serafino De Giorgi, Arianna Goracci, Daniele La Barbera, Claudio Mencacci, Gino Montagnani, Giorgio Pigato, Jarno Vannucchi & Antonio Vita. (2022) Treatment persistence with aripiprazole once monthly: a 4-year follow-up. Annals of General Psychiatry 21:1.
Crossref
Crossref
Chizimuzo T.C. Okoli, Amani Kappi, Tianyi Wang, Andrew Makowski & Andrew T. Cooley. (2021) The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis. International Journal of Mental Health Nursing 31:3, pages 469-535.
Crossref
Crossref
José Manuel Olivares & Andrea Fagiolini. (2022) Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis. Frontiers in Psychiatry 13.
Crossref
Crossref
Ofer Agid, Gary Remington, Carmen Fung, Natalie M. Nightingale, Marc Duclos & Gregory J. Anger. (2021) Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study. The Canadian Journal of Psychiatry 67:3, pages 226-234.
Crossref
Crossref
Vineet Dubey & Tulsi Ram Saini. (2022) Formulation development and pharmacokinetic studies of long acting in situ depot injection of risperidone. Brazilian Journal of Pharmaceutical Sciences 58.
Crossref
Crossref
Sarah E. Forster, Naomi N. Gancz, Marci L. Gaither, Gretchen L. Haas, Kelly D. Starver & Stuart R. Steinhauer. (2022) Barriers to Long-acting Injectable Antipsychotic Adherence During the COVID-19 Pandemic: Observations From One Site. Journal of Psychiatric Practice 28:6, pages 497-504.
Crossref
Crossref
Jasmina Mallet, Yann Le Strat, Caroline Dubertret & Philip Gorwood. 2022. Recovery and Major Mental Disorders. Recovery and Major Mental Disorders
131
151
.
Panita Maturavongsadit, Gayane Paravyan, Martina Kovarova, J. Victor Garcia & S. Rahima Benhabbour. (2021) A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery. International Journal of Pharmaceutics: X 3, pages 100068.
Crossref
Crossref
Hossein Kamali, Elham Khodaverdi, Ehsan Kaffash, Amir Sarem Saffari, Seyedeh Nesa Rezaeian Shiadeh, Ali Nokhodchi & Farzin Hadizadeh. (2020) Optimization and in Vitro Evaluation of Injectable Sustained-Release of Levothyroxine Using PLGA-PEG-PLGA. Journal of Pharmaceutical Innovation 16:4, pages 688-698.
Crossref
Crossref
Charles Dorflinger, Colleen LeHew, Heather Carey, Jennifer Roche-Desilets & Christopher J. Burant. (2021) Effectiveness of paliperidone palmitate one-month long-acting injection in obese vs. non-obese patients. Comprehensive Psychiatry 111, pages 152269.
Crossref
Crossref
Meaghan RoachDee LinMarlon GrafPriti PednekarJacquelyn W ChouCarmela BensonJalpa A Doshi. (2021) Schizophrenia population health management: perspectives of and lessons learned from population health decision makers. Journal of Managed Care & Specialty Pharmacy 27:10-a Suppl, pages S2-S13.
Crossref
Crossref
Meaghan RoachDee LinMarlon GrafPriti PednekarJacquelyn W ChouCarmela BensonJalpa A Doshi. (2021) Schizophrenia population health management: perspectives of and lessons learned from population health decision makers. Journal of Managed Care & Specialty Pharmacy 27:10-a Suppl, pages S1-S13.
Crossref
Crossref
Seyeon Chang, Young Sup Woo, Sheng-Min Wang, Hyun Kook Lim & Won-Myong Bahk. (2021) Patient Factors Influencing Outpatient Retention in Patients with Affective and Anxiety Disorders: A Retrospective Study. Clinical Psychopharmacology and Neuroscience 19:3, pages 545-553.
Crossref
Crossref
Panita Maturavongsadit, Roopali Shrivastava, Craig Sykes, Mackenzie L. Cottrell, Stephanie A. Montgomery, Angela D.M. Kashuba & S. Rahima Benhabbour. (2021) Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs. International Journal of Pharmaceutics 605, pages 120844.
Crossref
Crossref
Atsushi Kitamura, Takeshi Takagaki, Daisuke Nemoto, Yoshiko Tomita, Hironori Nishibe & Hiroyoshi Kakuyama. (2021)
Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D
2
Receptor Occupancy in Clinical Settings
. The Journal of Clinical Pharmacology 61:8, pages 1069-1080.
Crossref
Crossref
Lorenzo Tatini, Giulio D’Anna, Francesco Pietrini, Eugenia Calligaris, Andrea Ballerini & Valdo Ricca. (2021) Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10. International Clinical Psychopharmacology 36:4, pages 181-187.
Crossref
Crossref
Preeti Jacob, Siddhesh Shere & John Vijay Sagar Kommu. (2021) The use of first-generation long-acting injectable antipsychotics in children and adolescents—A retrospective audit from India. Asian Journal of Psychiatry 61, pages 102663.
Crossref
Crossref
Jenny Marlindawani Purba, Roymond H. Simamora & Evi Karota. (2021) The Relationship of Medication Adherence and Social Functioning of Persons with Schizophrenia in the Long-term Period. Open Access Macedonian Journal of Medical Sciences 9:T3, pages 16-18.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Michael Ming Cheuk Wong, Albert Kar Kin Chung, Timothy Ming Hong Yeung, David Tai Wai Wong, Che Kin Lee, Eric Lai, Gloria Fong Yeung Chan, Gregory Kai Lok Mak, Jessica Oi Yin Wong, Roger Man Kin Ng & Ki Yan Mak. (2021) Guidance on the clinical understanding and use of long‐acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements. CNS Neuroscience & Therapeutics 27:S1, pages 5-11.
Crossref
Crossref
Trevor A. Stump, Leigh Anne Nelson, Yifei Liu, Carrie R. Kriz, Courtney A. Iuppa, Lauren A. Diefenderfer, Shelby E. Lang, Ellie S. R. Elliot & Roger W. Sommi. (2021) The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection. Mental Health Clinician 11:1, pages 12-18.
Crossref
Crossref
José Manuel Olivares, Ana González-Pinto & Mario Páramo. (2021) Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. European Psychiatry 64:1.
Crossref
Crossref
Kimberly K. Scarsi & Susan Swindells. (2021) The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?. Journal of the International Association of Providers of AIDS Care (JIAPAC) 20, pages 232595822110090.
Crossref
Crossref
Christoph U. Correll, Edward Kim, Jennifer Kern Sliwa, Wayne Hamm, Srihari Gopal, Maju Mathews, Raja Venkatasubramanian & Stephen R. Saklad. (2021) Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs 35:1, pages 39-59.
Crossref
Crossref
Sanghoon Oh, Tae Young Lee, Minah Kim, Se Hyun Kim, Suehyun Lee, Sunwoo Cho, Ju Han Kim & Jun Soo Kwon. (2020) Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital. npj Schizophrenia 6:1.
Crossref
Crossref
Peter J. Weiden, Yangchun Du, Lisa von Moltke, Angela Wehr, Marjie Hard, Morteza Marandi & David P. Walling. (2020) Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. CNS Drugs 34:9, pages 961-972.
Crossref
Crossref
Nakao Iwata, Ataru Inagaki, Hiromi Sano, Kazunari Niidome, Yoshitsugu Kojima & Sakiko Yamada. (2020) Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Advances in Therapy 37:7, pages 3324-3336.
Crossref
Crossref
Christophe Roberge, Jean-Manuel Cros, Juliette Serindoux, Marie-Emérentienne Cagnon, Rémi Samuel, Tjasa Vrlinic, Pierre Berto, Anthony Rech, Joël Richard & Adolfo Lopez-Noriega. (2020) BEPO®: Bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG-PDLLA based in situ forming depots with flexible drug delivery kinetics modulation. Journal of Controlled Release 319, pages 416-427.
Crossref
Crossref
Charmi Patel, Bruno Emond, Marie-Hélène Lafeuille, Aurélie Côté-Sergent, Patrick Lefebvre, Neeta Tandon & Antoine C. El Khoury. (2019) Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. Drugs - Real World Outcomes 7:1, pages 19-29.
Crossref
Crossref
Antoine C. El KhouryDominic PilonLaura MorrisonNina Shak, Amanda LlanezaEdward KimPatrick Lefebvre. (2020) Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 26:2, pages 176-185.
Crossref
Crossref
Sam Debaveye, Delphine De Smedt, Bert Heirman, Shane Kavanagh & Jo Dewulf. (2019) Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections. BMC Health Services Research 19:1.
Crossref
Crossref
C.H. Arteaga Duarte, E. Fakra, C. Van Gils & P. Guillon. (2019) The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study. L'Encéphale 45:6, pages 459-467.
Crossref
Crossref
Kei Yoshimatsu, Andrea Elser, Melanie Thomas, James Dilley, Deborah Barnes, Alexandra Ballinger, Steven Wozniak & Christina Mangurian. (2019) Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population. Community Mental Health Journal 55:6, pages 979-982.
Crossref
Crossref
Andrew T Olagunju, Scott R Clark & Bernhard T Baune. (2019) Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome. Australian & New Zealand Journal of Psychiatry 53:6, pages 509-527.
Crossref
Crossref
Daniela PetrićValentino RačkiNadija GačoAna KaštelanMirjana Graovac. (2019) Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. Journal of Child and Adolescent Psychopharmacology 29:3, pages 197-204.
Crossref
Crossref
Celso Arango, Inmaculada Baeza, Miquel Bernardo, Fernando Cañas, Consuelo de Dios, Marina Díaz-Marsá, María Paz García-Portilla, Luis Gutiérrez-Rojas, José Manuel Olivares, Fernando Rico-Villademoros, Roberto Rodríguez-Jiménez, Eva María Sánchez-Morla, Rafael Segarra & Benedicto Crespo-Facorro. (2019) Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Revista de Psiquiatría y Salud Mental (English Edition) 12:2, pages 92-105.
Crossref
Crossref
Celso Arango, Inmaculada Baeza, Miquel Bernardo, Fernando Cañas, Consuelo de Dios, Marina Díaz-Marsá, María Paz García-Portilla, Luis Gutiérrez-Rojas, José Manuel Olivares, Fernando Rico-Villademoros, Roberto Rodríguez-Jiménez, Eva María Sánchez-Morla, Rafael Segarra & Benedicto Crespo-Facorro. (2019) Antipsicóticos inyectables de liberación prolongada para el tratamiento de la esquizofrenia en España. Revista de Psiquiatría y Salud Mental 12:2, pages 92-105.
Crossref
Crossref
A. Fagiolini, E. Aguglia, A. Ballerini, G. Callista, B. Carpiniello, M. Clerici, G. Corrivetti, P. De Fazio, S. De Filippis, S. De Giorgi, G. Favaretto, E. Ferri, G. Gargiulo, M.G. Giustra, D. La Barbera, G. Maina, C. Mencacci, G. Montagnani, A. Panariello, G. Pigato, A. Tortorella, L. Vernacotola & A. Vita. (2019) Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice. Psychiatry Research 272, pages 698-706.
Crossref
Crossref
Jennifer N. Alastanos, Chris Paxos & Jessica Emshoff. (2019) Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting. Mental Health Clinician 9:1, pages 18-23.
Crossref
Crossref
Kruti Joshi, Lian Mao, David M. Biondi & Robert Millet. (2018) The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia. BMC Psychiatry 18:1.
Crossref
Crossref
Jennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, Maju Mathews, Srihari Gopal, Erica Elefant, Dean Najarian & Larry Alphs. (2018) An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. Perspectives in Psychiatric Care 54:4, pages 530-538.
Crossref
Crossref
E. Chui, K.L. Wong, K.Y. Chan & M. Wong. (2018) Validation study of the Brief Medication Adherence Scale (BMAS) in patients with schizophrenia and related disorders in Hong Kong. Asian Journal of Psychiatry 37, pages 154-160.
Crossref
Crossref
Francesco Pietrini, Giulio D’Anna, Lorenzo Tatini, Gabriela Alina Talamba, Costanza Andrisano, Enrico Calderani, Mara Manetti, Paolo Rossi Prodi, Valdo Ricca & Andrea Ballerini. (2018) Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study. European Psychiatry 53, pages 58-65.
Crossref
Crossref
Sean Askin, Min Zhao, Andrea D. Gonçalves, Simon Gaisford & Duncan Q. M. Craig. (2018) The Development of Quasi-isothermal Calorimetry for the Measurement of Drug–Polymer Miscibility and Crystallization Kinetics: Olanzapine-Loaded PLGA Microparticles. Molecular Pharmaceutics 15:8, pages 3332-3342.
Crossref
Crossref
Kruti Joshi, Erik Muser, Yihua Xu, Phil Schwab, Manasi Datar & Brandon Suehs. (2018) Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. Journal of Comparative Effectiveness Research 7:8, pages 723-735.
Crossref
Crossref
Stuart J. Lee, Anthony de Castella, Simon Stafrace, Sandra Keppich-Arnold & Jayashri Kulkarni. (2018) Retrospective audit of people treated with long-acting antipsychotic injectable medications: Usage patterns and outcomes. Schizophrenia Research 197, pages 572-573.
Crossref
Crossref
Tianmei Si, Nan Li, Huafei Lu, Shangli Cai, Jianmin Zhuo, Christoph U Correll, Lili Zhang & Yu Feng. (2018) Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. Journal of Psychopharmacology 32:6, pages 691-701.
Crossref
Crossref
Adriana ForteaDaniel IlzarbeLaura EspinosaMireia SolerdelcollClara de CastroGiovanni OrioloGisela SugranyesInmaculada Baeza. (2018) Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study. Journal of Child and Adolescent Psychopharmacology 28:4, pages 252-257.
Crossref
Crossref
Daniel Saltzstein, Neal D. Shore, Judd W. Moul, Franklin Chu, Raoul Concepcion, Stephan de la Motte, John A. McLane, Stuart Atkinson, Alex Yang & E. David Crawford. (2017)
Pharmacokinetic and pharmacodynamic comparison of subcutaneous
versus
intramuscular leuprolide acetate formulations in male subjects
. Therapeutic Advances in Urology 10:2, pages 43-50.
Crossref
Crossref
Dieter Naber, Ross A. Baker, Anna Eramo, Carlos Forray, Karina Hansen, Christophe Sapin, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Jean-Yves Loze & Steven G. Potkin. (2018) Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophrenia Research 192, pages 205-210.
Crossref
Crossref
Atul P. Sherje & Vaishali Londhe. (2017) Development and Evaluation of pH-Responsive Cyclodextrin-Based in situ Gel of Paliperidone for Intranasal Delivery. AAPS PharmSciTech 19:1, pages 384-394.
Crossref
Crossref
Sharon Ashong, Irene A. Kretchy, Barima Afrane & Ama de-Graft Aikins. (2018) Patterns of Prescription of Psychotropic Medications and Their Adherence among Patients with Schizophrenia in Two Psychiatric Hospitals in Accra, Ghana: A Cross-Sectional Survey. Psychiatry Journal 2018, pages 1-10.
Crossref
Crossref
E. Calderani, F. Pietrini, I. Burian, F. Chiarello, D. Dahlke, S. Gemignani, P. Marino, G.A. Talamba, L. Poli, A. Santangelo, V. Ricca & A. Ballerini. (2020) Long acting antipsychotics treatment of schizophrenia: A 24-month prospective study on patient's attitude towards treatment. European Psychiatry 41:S1, pages S188-S188.
Crossref
Crossref
Vanya Hamrin, Vaughn G. Sinclair & Virginia Gardner. (2017) Theoretical Approaches to Enhancing Motivation for Adherence to Antidepressant Medications. Archives of Psychiatric Nursing 31:2, pages 223-230.
Crossref
Crossref
Benedicto Crespo-Facorro, Miguel Bernardo, Josep Maria Argimon, Manuel Arrojo, Maria Fe Bravo-Ortiz, Ana Cabrera-Cifuentes, Julián Carretero-Román, Manuel A. Franco-Martín, Paz García-Portilla, Josep Maria Haro, José Manuel Olivares, Rafael Penadés, Javier del Pino-Montes, Julio Sanjuán & Celso Arango. (2017) Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. Revista de Psiquiatría y Salud Mental (English Edition) 10:1, pages 4-20.
Crossref
Crossref
Benedicto Crespo-Facorro, Miguel Bernardo, Josep Maria Argimon, Manuel Arrojo, Maria Fe Bravo-Ortiz, Ana Cabrera-Cifuentes, Julián Carretero-Román, Manuel A. Franco-Martín, Paz García-Portilla, Josep Maria Haro, José Manuel Olivares, Rafael Penadés, Javier del Pino-Montes, Julio Sanjuán & Celso Arango. (2017) Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. Revista de Psiquiatría y Salud Mental 10:1, pages 4-20.
Crossref
Crossref
Yvette N. Lamb & Gillian M. Keating. (2016) Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia. Drugs 76:16, pages 1559-1566.
Crossref
Crossref
Mahadevabharath R. Somayaji, Debarun Das & Andrzej Przekwas. (2016) A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables. Clinical Pharmacokinetics 55:10, pages 1179-1190.
Crossref
Crossref
Fabienne Chou, Earle Reome & Patricia Davis. (2016) Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder. Mental Health Clinician 6:5, pages 254-259.
Crossref
Crossref
F. Pietrini, M. Spadafora, L. Tatini, G.A. Talamba, C. Andrisano, G. Boncompagni, M. Manetti, V. Ricca & A. Ballerini. (2020) LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment. European Psychiatry 37, pages 35-42.
Crossref
Crossref
Stephanie PopeSolomon G. Zaraa. (2016) Efficacy of Long-Acting Injectable Antipsychotics in Adolescents. Journal of Child and Adolescent Psychopharmacology 26:4, pages 391-394.
Crossref
Crossref
Sarah Fidler, Jintanat Ananworanich, Linos Vandekerckhove, Maja Kiselinova, Alexandra Schuetz, Jaime H. Vera, Ellen Dwyer & Jasmini Alagaratnam. (2016) Highlights from the Conference on Retroviruses and Opportunistic Infections 2016. Journal of Virus Eradication 2:2, pages 124-130.
Crossref
Crossref
Timothy Peters-Strickland, Ross A Baker, Robert D McQuade, Na Jin, Anna Eramo, Pamela Perry, Brian R Johnson, Anna Duca & Raymond Sanchez. (2015) Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. npj Schizophrenia 1:1.
Crossref
Crossref
Marc De Hert, Jan Sermon, Paul Geerts, Kristof Vansteelandt, Joseph Peuskens & Johan Detraux. (2015) The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. CNS Drugs 29:8, pages 637-658.
Crossref
Crossref
Ludger Hargarter, Pierre Cherubin, Paul Bergmans, Sofia Keim, Elmars Rancans, Yasin Bez, Eduard Parellada, Bernardo Carpiniello, Pierre Vidailhet & Andreas Schreiner. (2015) Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 58, pages 1-7.
Crossref
Crossref
S. Heres, M. Lambert & R. Vauth. (2020) Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. European Psychiatry 29:S2, pages 1409-1413.
Crossref
Crossref
Victor Siciliano Soares, Claudiane Salles Daltio & Cecília Attux. (2014) Antipsicóticos de longa ação como facilitadores da adesão no tratamento da esquizofrenia: relato de caso. Debates em Psiquiatria 4:5, pages 32-34.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Julius F. Remenar. (2014) Making the Leap from Daily Oral Dosing to Long-Acting Injectables: Lessons from the Antipsychotics. Molecular Pharmaceutics 11:6, pages 1739-1749.
Crossref
Crossref
Daniel C. Javitt. (2014) Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia. Current Treatment Options in Psychiatry 1:2, pages 107-120.
Crossref
Crossref